TRUDHESA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRUDHESA (TRUDHESA).
TRUDHESA is a fixed-dose combination of sumatriptan (a serotonin 5-HT1B/1D receptor agonist) and naproxen sodium (a nonsteroidal anti-inflammatory drug). Sumatriptan causes vasoconstriction of intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides, while naproxen inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis.
| Metabolism | Sumatriptan is metabolized primarily by monoamine oxidase A (MAO-A). Naproxen is metabolized by CYP2C9 (major) and CYP1A2 (minor). |
| Excretion | Trudhesa (dihydroergotamine mesylate) is primarily eliminated via hepatic metabolism, with approximately 10% excreted unchanged in urine and 90% as metabolites in bile/feces. |
| Half-life | Terminal elimination half-life is approximately 2.4 hours (range 1.7-3.6 hours) following intravenous administration. Clinical context: Due to rapid clearance, repeated dosing is recommended for acute migraine attacks. |
| Protein binding | Approximately 90-93% bound to plasma proteins, primarily to albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 14 L/kg (range 10-20 L/kg), indicating extensive tissue distribution, including binding to serotonin receptors in the CNS. |
| Bioavailability | Intranasal administration: Absolute bioavailability approximately 15-20% (range 10-30%), due to extensive first-pass hepatic metabolism. |
| Onset of Action | Intranasal administration: Onset of relief within 30 minutes; peak effect at 1-2 hours. |
| Duration of Action | Duration of therapeutic effect typically lasts 4-6 hours. Clinical note: Some patients may require a second dose if symptoms recur within 24 hours, with a maximum of 3 mg/day. |
| Molecular Weight | 214.22 |
10 mg intranasally once, may repeat after 2 hours if needed; maximum 20 mg per 24 hours.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment; no data for severe impairment (eGFR <30 mL/min/1.73 m2). |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh class C); use with caution in moderate impairment (Child-Pugh class B) with no specific dose adjustment defined. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended, but consider potential increased sensitivity to adverse effects due to comorbidities or concomitant medications. |
| 1st trimester | Avoid unless clearly needed. Limited human data; animal studies show increased risk of cardiovascular defects and neural tube defects at high doses. Considered a known human teratogen. |
| 2nd trimester | Avoid if possible; associated with fetal growth restriction and premature closure of ductus arteriosus. Use only if maternal benefit outweighs fetal risk. |
| 3rd trimester | Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment. Discontinue before 30 weeks. |
Clinical note
Comprehensive clinical and safety monograph for TRUDHESA (TRUDHESA).
| Placental transfer | Crosses the placenta readily; cord blood concentrations similar to maternal levels. |
| Breastfeeding | Excreted into breast milk in low concentrations (milk-to-plasma ratio ~0.01-0.03). No adverse effects observed in infants after short-term maternal use. Caution with prolonged therapy due to potential for gastrointestinal effects or bleeding. |
■ FDA Black Box Warning
Cardiovascular Risk: NSAIDs, including naproxen, increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular risk factors or existing cardiovascular disease are at greater risk.
| Serious Effects |
Hypersensitivity to any NSAIDHistory of aspirin or NSAID-induced asthmaActive peptic ulcer disease or GI hemorrhageSevere renal impairment (eGFR <30 mL/min)Severe hepatic failure (Child-Pugh class C)Perioperative pain in CABG surgeryThird trimester of pregnancy (after 30 weeks)
| Precautions | Cardiovascular and cerebrovascular effects; risk of myocardial infarction, stroke, and hypertension; gastrointestinal bleeding (NSAID-related); serotonin syndrome with concomitant serotonergic drugs; renal effects; anaphylactic reactions; exacerbation of asthma; sulfonamide allergy (cross-reactivity). |
| Food/Dietary | Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4 and may increase ergotamine toxicity. No other significant food interactions reported. |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Trimester 1: Increased risk of congenital abnormalities, particularly neural tube defects, due to topiramate exposure. Trimester 3: Risk of transient neonatal hyperbilirubinemia and sulfonamide-related adverse effects. |
| Fetal Monitoring | Monitor serum topiramate levels, liver function, renal function, and serum bicarbonate (risk of metabolic acidosis). Obtain fetal ultrasound for neural tube defects at 18-20 weeks. Monitor for signs of neonatal jaundice and kernicterus. |
| Fertility Effects | No significant impairment of fertility reported in clinical studies. May cause anovulatory cycles due to weight loss or hormonal effects. |
| Clinical Pearls | TRUDHESA (dihydroergotamine mesylate) is an intranasal formulation for acute migraine. Administer one spray (0.5 mg) in each nostril, repeated after 15 minutes if needed (total 2 mg). Avoid in basilar or hemiplegic migraine due to vasospasm risk. Max dose: 3 mg/day, 4 mg/week. Contraindicated with CYP3A4 inhibitors (e.g., macrolides, azoles, protease inhibitors) due to ergotism risk. Monitor for signs of ischemia. |
| Patient Advice | Use at the first sign of migraine; not for prevention. · Prime the pump 4 times before first use or if not used for 7+ days. · Do not exceed 2 sprays per nostril per attack or 8 sprays total per week. · Avoid within 24 hours of other triptans or ergotamines. · Seek medical help if symptoms of chest tightness, severe abdominal pain, or numbness occur. |